Subsequently, we established stable expression of Galectin-9 in ATXN3 wild-type and KO colon cancer cells to investigate whether reintroducing Galectin-9 expression could mitigate the heightened tumor progression observed upon ATXN3-targeted suppression. Here, ATXN3 is linked to malignant colon neoplasm.